Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 1-Year Low Following Analyst Downgrade

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares reached a new 52-week low on Thursday after JPMorgan Chase & Co. lowered their price target on the stock from $46.00 to $33.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Ascentage Pharma Group International traded as low as $14.55 and last traded at $14.6290, with a volume of 9,357 shares. The stock had previously closed at $14.94.

Several other research analysts have also commented on AAPG. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $44.75.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The business’s 50 day moving average is $16.71 and its 200 day moving average is $19.34.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million for the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.